INTERVIEW: Green Cross Looks Abroad To Expand
This article was originally published in PharmAsia News
Executive Summary
Green Cross Holdings, which has South Korea's leading biopharma company Green Cross Corp. as its affiliate, talks to PharmAsia News about its strategies on acquisitions, international business plans and R&D updates on the sidelines of Biologics World Korea 2015.
You may also be interested in...
Green Cross Halts US, Europe GreenGene F Trials To Focus On China
Green Cross has overhauled the global development strategy for its hemophilia A therapy GreenGene F, halting slow-progressing Phase III trials in the US and Europe and shifting its focus instead to the fast-growing China market.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.